AMT Medical secures €22M to transform heart bypass surgery
The scaleup developed a minimally invasive approach to eliminate the need for traditional open-heart bypass surgery.
Published on April 17, 2025
Team IO+ selects and features the most important news stories on innovation and technology, carefully curated by our editors.
Dutch biotech company AMT Medical has successfully closed a €22 million Series B funding round, aimed at advancing its innovative ELANA® Heart Bypass System. This system is pioneering a shift in cardiac surgery by utilizing a minimally invasive, beating-heart approach that seeks to eliminate the need for traditional open-heart bypass surgery.
Open-heart bypass surgery, also known as coronary artery bypass grafting (CABG), is a procedure to treat blocked or narrowed coronary arteries. It involves rerouting blood flow around the blocked areas using a healthy blood vessel (graft) from another part of the body. AMT Medical’s method, through sutureless procedures and minimally invasive techniques, aims to significantly reduce recovery times and complications associated with traditional surgery.
With contributions from Bender Analytical Holding, Invest-NL, and the European Innovation Council, this funding will accelerate the completion of European trials by late 2025, with anticipated CE marking by 2026. The ELANA® system, equipped with sutureless anastomosis technology, is designed to drastically reduce recovery times, cost, and risks associated with conventional procedures.
Game-changing impact of AMT Medical technology
The ELANA® system by AMT Medical is poised to transform heart surgery by offering several significant advantages: it standardizes procedures to reduce dependency on surgeon skills, avoids using heart-lung machines, and significantly cuts down recovery times and associated risks like infections and strokes. This system is built on the ELANA technique, originally developed for brain surgery, showcasing its versatility and innovation.
Rutger Tulleken, CEO of AMT Medical, emphasized the importance of this financial boost, highlighting its role in validating the company's mission to make traditional open-heart bypass obsolete. The ELANA® system promises improved patient outcomes and redefines postoperative recovery by potentially allowing for same-day discharges.
